The strategic partnership leverages AI and robotics, a novel therapeutic agent across oncology, immunology, inflammation, neurology, and metabolic diseases.
Cambridge, MA., August 6, 2025 /prnewswire/-xtalpi (2228.hk) has announced a transformational strategic collaboration with Dovetree Medicines, a leading global technology company in the integration of artificial intelligence (AI) and robotics for the discovery of drugs and materials, and a biotechnology pioneer founded by renowned drug developers. Gregory Veridin. Collaboration is worth it $59 billionrepresents one of the biggest commitments to AIL and Robotics-led pharmaceutical R&D to date.
Under the agreement, Dovetree will acquire exclusive global rights to develop and commercialize a portfolio of innovative therapies created through the partnership. XTALPI received prepayment $51 million I'm qualified for $49 million In addition to additional short-term payments, development and commercial milestones, and total tiered royalties $5.89 billion.
This collaboration combines XTALPI's integrated drug discovery capabilities with Dovetree's deep biological expertise in selecting and verifying new targets of high therapeutic potential. Together, the company will focus on the development of candidates within the class through oncology, immunology, inflammatory diseases, neuropathy, and metabolic dysregulation with important unmet needs. This partnership will promote Dovetree's selected pipeline of projects targeting historically challenging mechanisms, with plans to expand the joint R&D capabilities of new modalities like molecular adhesives.
dovetree drugs were founded by a doctor Gregory Veridinan internationally respected scientist, entrepreneur, and veteran investor in the biopharmaceutical field, with outstanding results both in academia and industry. He has co-founded more than 12 biopharmaceutical companies, including five or more publicly listed companies, including Enanta Pharmaceuticals (NASDAQ:ENTA), Rein Therapeutics (NASDAQ: RNTX), and Wave Life Sciences (NASDAQ: WVE). Recognized for creating the “drug-free” concept, Dr Verdine pioneered a unique molecular adhesive and peptide technology platform, successfully applied drug development to “constant” proteins such as RAS, MYC and β-catenin. He has co-developed three FDA-approved drugs, and has now attracted more than 12 additional candidates in clinical development.
XTALPI has developed an intelligent de novo creation platform that spans small molecules, biology, antibody drug analogs (ADCs), and molecular adhesives. This multimodal feature allows for efficient investigation of parallel drug development approaches for a single target, unlocking the broader chemical space. By integrating quantum physics prediction, AI-driven molecular design, and large-scale robotic lab-in-the-loop, XTALPI dramatically accelerates the drug discovery workflow from target analysis and molecular generation to affinity prediction, ADMET evaluation and synthesis design, to increased accuracy and efficiency, to target analysis and molecular generation, ADMET evaluation and synthesis design. Through extensive partnerships with innovative pharmaceutical companies, XTALPI's platform has been accumulated with a vast data set of rigorously validated and standardized experimental data in real projects. Highly accurate calculation data Continuously optimize the model within a closed feedback loop.
Doctor Gregory Veridin“We're looking forward to seeing you in the future,” said Dovetree Founder and CEO. “Xtalpi's unique platform has the potential to transform the deep uncertainty of drug discovery into a quantifiable engineering solution for patients around the world.”
Doctor shuhao wenThe Chairman of XTALPI commented: “Dr. Verdin and Dovetry bring about exceptional biological insights, business vision and successful translation, fully complementing the platform's strengths in the generation, design and verification of high-throughput molecules. We work closely with our core technologies and key innovators to help us build a diverse pipeline of impactful pharmaceutical products.”
About dovetree drugs
Dovetree Medicines is a biotechnology company dedicated to discovering the first-ever drugs of its class for diseases with profound medical needs. Founded and led by a renowned scientist – Discoverer Dr. Gregory VeridinDovetree integrates deep biological insights and advanced AI to unlock new therapeutic pathways, accelerate the development of transformative drugs, and translates pioneering science into meaningful patient benefits.
About Xtalpi
Xtalpi Holdings Limited (Xtalpi, 2228.hk) was founded in 2015 by three physicists. Massachusetts Institute of Technology (mit). This is an innovative R&D platform powered by quantum physics, artificial intelligence and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing and standardized automation systems, XTALPI offers digital and intelligent R&D solutions to companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals and cosmetics industry.
Source Xtalpi Inc.
